Trial Profile

A phase IV study to evaluate the primary and booster immune responses of UK infants receiving a licensed 6-in-1 DTaP/IPV/Hib/HBV vaccine (Infanrix-HexaTM) with a 13-valent pneumococcal conjugate vaccine and incorporating a randomisation study of a single dose of 3 different meningococcal group C conjugate vaccines at 3 months of age

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 05 Oct 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa) (Primary) ; Hib-meningococcal vaccine group C conjugate; Measles mumps and rubella virus vaccine-(Priorix); Meningococcal vaccine group C conjugate; Pneumococcal 13-valent CRM197 vaccine conjugate
Indications Hepatitis B
Focus Pharmacodynamics
Acronyms Infanrix-Hexa

15 Mar 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
04 Apr 2017 Status changed from active, no longer recruiting to completed.
15 Jun 2016 Planned End Date changed from 1 Jul 2016 to 1 Dec 2016.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com